Ascites-derived pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised medicine.

ABSTRACT:

Background

Challenges in developing drugs for pancreatic ductal adenocarcinoma (PDAC) include obtaining metastatic cancer tissue for research and validating biomarkers predicative for personalised therapeutic decisions. We have recently developed a novel therapeutic model for PDAC to address these challenges based on the isolation of viable PDAC cells derived from ascites fluid.

Methods

Ascites fluid was obtained from PDAC patients undergoing palliative paracentesis. Ascites-derived PDAC primary cells were isolated, cultured and characterised in ovo and in vitro.

Results

We successfully established ascites-derived primary cell cultures within 2-7 days from 92% (93 out of 101) of the ascites fluid samples obtained (from 36 different patients). Homogeneous epithelial PD

SUBMITTER: Golan T 

PROVIDER: S-EPMC4007225 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature